Clinical Trials Browser

Phase 1/2 × Terminated × Oligodendroglioma × Clear all

NCT05737212 2025-02-21

Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas

Phase 1/2 Terminated

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT01721577 2023-05-22

AXL1717

Phase 1/2 Terminated

10 enrolled 8 charts

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT01884740 2022-08-09

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Phase 1/2 Terminated

13 enrolled 6 charts

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT01110876 2021-08-25

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Phase 1/2 Terminated

21 enrolled 8 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT01189240 2015-12-14

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

Phase 1/2 Terminated

13 enrolled 13 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT00074334 2009-10-21

TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma

Phase 1/2 Terminated

Familial ependymoma, Astrocytoma, Oligodendroglioma, Central Nervous System Neoplasms